RX Institutional Services is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
inVentiv Clinical Solutions is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Caring physicians, caring for people. cCARE, Californias largest private practice oncology group, focuses on compassion, prevention, research and wellness.